Literature DB >> 15221010

Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin.

Els Robanus-Maandag1, Marco Giovannini, Martin van der Valk, Michiko Niwa-Kawakita, Vincent Abramowski, Cristina Antonescu, Gilles Thomas, Anton Berns.   

Abstract

Previously, we have mimicked human neurofibromatosis type 2 (NF2) in conditional Nf2 mutant (P0Cre;Nf2flox2/flox2) mice. Schwannomas, characteristic for NF2, were found at low frequency in older mice. Here, we report that these mice, upon additional hemizygosity for p53, rapidly develop multiple tumours showing features consistent with malignant peripheral nerve sheath tumours. Thus, p53 hemizygosity promotes tumorigenesis of mutant Nf2 peripheral nerve cells. In contrast, young P0Cre;Nf2flox2/+;p53+/- cis mice mainly succumb to Nf2/p53-related osteogenic tumours. Therefore, Cre-mediated early biallelic loss of Nf2 function in neural crest-derived cells hemizygous for p53 results in resistance to osteogenic tumours and increased susceptibility to peripheral nerve sheath tumours.

Entities:  

Mesh:

Year:  2004        PMID: 15221010     DOI: 10.1038/sj.onc.1207858

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.

Authors:  Hongsai Chen; He Huang; Jingjing Zhao; Zhigang Wang; Mengling Chang; Lu Xue; Weidong Zhu; Yongchuan Chai; Gen Li; Zhaoyan Wang; Hao Wu
Journal:  J Neurooncol       Date:  2019-05-02       Impact factor: 4.130

2.  Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature.

Authors:  Anandh Balasubramaniam; Patrick Shannon; Mojgan Hodaie; Normand Laperriere; Howard Michaels; Abhijit Guha
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

Review 3.  Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Authors:  Sarah Beltrami; Richard Kim; Jennifer Gordon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

4.  p53 performs an essential role in mediating the oncogenic stimulus triggered by loss of expression of neurofibromatosis type 2 during in vitro tumor progression.

Authors:  Xiye Li; Hongsai Chen; Lu Xue; Xiuhong Pang; Xiaoman Zhang; Zhengjie Zhu; Weidong Zhu; Zhaoyan Wang; Hao Wu
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 5.  The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.

Authors:  Heinrich Kovar; Lisa Bierbaumer; Branka Radic-Sarikas
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

6.  Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.

Authors:  Daniel Menendez; Thuy-Ai Nguyen; Johannes M Freudenberg; Viju J Mathew; Carl W Anderson; Raja Jothi; Michael A Resnick
Journal:  Nucleic Acids Res       Date:  2013-06-17       Impact factor: 16.971

7.  Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.

Authors:  Michel Kalamarides; Anat O Stemmer-Rachamimov; Masaya Takahashi; Zhi-Yan Han; Fabrice Chareyre; Michiko Niwa-Kawakita; Peter M Black; Rona S Carroll; Marco Giovannini
Journal:  Brain Pathol       Date:  2007-10-09       Impact factor: 6.508

Review 8.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Authors:  Michael D Deel; Jenny J Li; Lisa E S Crose; Corinne M Linardic
Journal:  Front Oncol       Date:  2015-09-02       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.